ORLANDO, Fla., Dec. 12 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported the presentation of
results of several clinical trials of VELCADE(R) (bortezomib) for Injection
in combination with a variety of agents, including DOXIL(R) (pegylated
liposomol doxorubicin) and dexamethasone, for the treatment of newly
diagnosed multiple myeloma (MM) patients. Studies showed VELCADE
combination therapy produced very good partial response and complete
response (VGPR/CR) rates as high as 53 percent as induction therapy, which
improved to 79 percent following autologous stem cell transplantation
(ASCT). In a study of VELCADE in combination with dexamethasone, the
one-year survival rate was 92 percent after a median follow up of 24
months. These findings were reported at the 48th Annual Meeting and
Exposition of the American Society of Hematology (ASH), December 9-12,
2006, in Orlando, Fla.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
"Evidence continues to build that VELCADE based regimens provide high
VGPR/CR rates in front-line patients as induction therapy prior to stem
cell transplantation," said Nancy Simonian, M.D., Senior Vice President and
Chief Medical Officer, Millennium. "With these high CR rates, we believe we
are starting to see the benefit of VELCADE on improved post-transplant
outcomes."
Long-Term Follow Up of Patients Treated with VELCADE (Bortezomib) Alone
and in Combination with Dexamethasone as Front-line Therapy for Multiple
Myeloma (Abstract #796)
The long-term follow up of a Phase II clinical trial evaluated VELCADE
in combination with dexamethasone in 48 evaluable newly diagnosed MM
patients. Patients with measurable disease received VELCADE at 1.3 mg/m2 on
days 1, 4, 8, and 11 of a three-week cycle for up to six cycles. Oral
dexamethasone at 40 mg was added to the treatment regimen on the day of and
day after VELCADE for patients not achieving partial response (PR) after
two cycles or for patients not achieving a CR after four cycles. Responses
were assessed using modified European Group for Blood and Marrow
Transplantation (EBMT) criteria. The study was presented by Sundar
Jagannath, M.D., of St. Vincent's Comprehensive Cancer Center, New York,
N.Y. on behalf of the Aptium Oncology Research Network, Los Angeles, Calif.
Results showed:
-- Overall response rate (ORR) was 88 percent including an 18 percent
CR/near complete response (nCR) rate and a 20 percent VGPR rate
-- For all patients, with a median follow up of 27 months, median overall
survival had not yet been reached; one- and two-year survival rates
were 92 and 85 percent, respectively
-- For patients not proceeding to ASCT, with a median follow up of 27
months, two-year survival rate was 81 percent
-- Collection of stem cells was not impaired for patients proceeding to
ASCT
-- Therapy was well tolerated; the most frequent adverse events were
sensory neuropathy/neuropathic pain, fatigue and constipation
High Rate of Complete and near Complete Responses after Initial Therapy
with VELCADE (Bortezomib), DOXIL, and Dexamethasone (VDD) Is Further
Increased after Autologous Stem Cell Transplantation (Abstract #3093)
The Phase II clinical trial evaluated VELCADE in combination with DOXIL
plus dexamethasone (VDD) in 28 evaluable newly diagnosed MM patients. The
primary goals of the study were to measure CR/nCR of VDD pre- and post-
transplantation and to explore whether an improved quality of response
prior to ASCT would improve the overall chances of survival
post-transplantation. Responses were assessed using modified EBMT criteria.
Six three-week cycles of VELCADE at 1.3 mg/m2 were administered on days 1,
4, 8, and 11. DOXIL at 30 mg/m2 was administered on day four and
dexamethasone at 40 mg on days one to four for the first 10 patients and at
20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 for the remaining patients (for a
total dose of 160 mg of dexamethasone per cycle). The data were presented
by Andrzej Jakubowiak, M.D., Ph.D., of the University of Michigan
Comprehensive Cancer Center in Ann Arbor, Mich. Results showed:
-- VDD achieved a strong ORR as induction therapy
- ORR was 89 percent, with a CR/nCR of 32 percent and with 53 percent
achieving a CR/VGPR
-- VDD appeared to improve probability of achieving CR/nCR and VGPR after
transplantation compared to results from randomized studies with single
or tandem transplantation
- In the 17 patients who went on to ASCT, ORR improved to 96 percent
with 54 percent achieving CR/nCR and 79 percent achieving a CR/VGPR
- Collection of stem cells was not impaired by this regimen
-- The most common adverse events were fatigue, pneumonia/infection and
neuropathy (only mild)
VELCADE (Bortezomib) and Pegylated Liposomal Doxorubicin as Induction
Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and
Leukemia Group B Study 10301 (Abstract #797)
The multicenter Phase II study assessed the safety and efficacy of the
steroid-free combination of VELCADE and DOXIL in 57 evaluable newly
diagnosed MM patients as induction therapy prior to ASCT. Responses were
assessed using modified EBMT. VELCADE was administered at 1.3 mg/m2 on days
1, 4, 8 and 11 of a 21-day cycle, along with DOXIL at 30 mg/m2 on day four,
for a maximum of eight cycles. Data from 29 evaluable patients were
presented by Robert Orlowski, M.D., Ph.D., of the University of North
Carolina at Chapel Hill for the Cancer and Leukemia Group B cooperative
group. Results showed:
-- After induction therapy prior to stem cell transplantation, ORR was 79
percent with a 28 percent CR/nCR rate
-- Treatment did not affect stem cell collection in patients evaluable for
this endpoint
-- Therapy was well tolerated; the most common adverse events were
neutropenia, thrombocytopenia (hematologic), fatigue and sensory
neuropathy (non-hematologic)
VELCADE is the U.S. market leader for relapsed MM. Previous studies in
relapsed MM have demonstrated single-agent VELCADE has unprecedented
survival. In newly diagnosed patients, VELCADE based therapies have
achieved transplant- like results with ORRs of up to 95 percent and CR/nCR
rates of up to 43 percent. The studies presented today along with the
interim data from the Phase III trial presented by the Intergroupe
Francophone du Myelome on Sunday continue to show some of the highest
recorded CR/nCR rates for a therapeutic agent in the treatment of
front-line MM.
About Multiple Myeloma
MM is the second most common hematologic malignancy and although the
disease is predominantly a cancer of the elderly (the average age of onset
is 65 to 70 years of age), recent statistics indicate both an increasing
incidence and a younger age of onset. In the U.S., more than 50,000
individuals have MM and over 15,000 new cases are diagnosed each year.
Worldwide there are approximately 74,000 new cases and over 45,000 deaths
annually.(1)
About VELCADE
VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium
is responsible for commercialization of VELCADE in the U.S.; Janssen-Cilag
is responsible for commercialization in Europe and the rest of the world.
Janssen Pharmaceutical K.K. is responsible for commercialization in Japan.
For a limited period of time, Millennium and Ortho Biotech Inc. will
co-promote VELCADE in the U.S. VELCADE also is approved in the European
Union after first relapse.
VELCADE is indicated for the treatment of patients with multiple
myeloma who have received at least one prior therapy. VELCADE is indicated
for the treatment of patients with mantle cell lymphoma (MCL) who have
received at least one prior therapy. VELCADE is contraindicated in patients
with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be
administered under the supervision of a physician experienced in the use of
antineoplastic therapy.
Risks associated with VELCADE therapy include new or worsening
peripheral neuropathy, hypotension observed throughout therapy, cardiac and
pulmonary disorders, gastrointestinal adverse events, thrombocytopenia,
neutropenia and tumor lysis syndrome. Women of childbearing potential
should avoid becoming pregnant while being treated with VELCADE. Cases of
severe sensory and motor peripheral neuropathy have been reported. The
long-term outcome of peripheral neuropathy has not been studied in mantle
cell lymphoma. Acute development or exacerbation of congestive heart
failure, and/or new onset of decreased left ventricular ejection fraction
has been reported, including reports in patients with few or no risk
factors for decreased left ventricular ejection fraction. There have been
rare reports of acute diffuse infiltrative pulmonary disease of unknown
etiology such as pneumonitis, interstitial pneumonia, lung infiltration and
Acute Respiratory Distress Syndrome (ARDS) in patients receiving VELCADE.
Some of these events have been fatal. A higher proportion of these events
have been reported in Japan. There have been rare reports of RPLS in
patients receiving VELCADE. RPLS is a rare, reversible, neurological
disorder which can present with seizure, hypertension, headache, lethargy,
confusion, blindness, and other visual and neurological disturbances.
VELCADE is associated with thrombocytopenia and neutropenia. There have
been reports of gastrointestinal and intracerebral hemorrhage in
association with VELCADE. Transfusions may be considered. Complete blood
counts (CBC) should be frequently monitored during treatment with VELCADE.
Rare cases of acute liver failure have been reported in patients receiving
multiple concomitant medications and with serious underlying medical
conditions.
Safety Data: In 1163 patients in MM and MCL studies, the most commonly
reported adverse events were asthenic conditions (64%), nausea (55%),
diarrhea (52%), constipation (41%), peripheral neuropathy (39%),
thrombocytopenia (36%), appetite decreased, including reports of anorexia
(36%), pyrexia (34%), vomiting (33%) and anemia (29%). Twenty percent of
patients reported at least one episode of grade 4 toxicity; the most common
grade 4 toxicities were thrombocytopenia (5%) and neutropenia (3%). Fifty
percent of patients reported serious adverse events (SAEs). The most
commonly reported SAEs were pneumonia (7%), pyrexia (6%), diarrhea (5%),
vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each
3%).
For more information about VELCADE clinical trials, patients and
physicians can contact the Millennium Medical Product Information
Department at 1-866-VELCADE (1-866-835-2233).
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company
based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has
a robust clinical development pipeline of product candidates. The Company's
research, development and commercialization activities are focused in two
therapeutic areas: oncology and inflammation. By applying its knowledge of
the human genome, understanding of disease mechanisms and industrialized
drug discovery platform, Millennium is developing an exciting pipeline of
innovative product candidates. The Company's website is http://www.millennium.com.
This press release contains "forward-looking statements," including
statements about the Company's growth and development of products. Various
important risks may cause the Company's actual results to differ materially
from the results indicated by these forward-looking statements, including:
adverse results in its drug discovery and clinical development programs;
failure to obtain patent protection for its discoveries; commercial
limitations imposed by patents owned or controlled by third parties; the
Company's dependence upon strategic alliance partners to develop and
commercialize products and services based on its work; difficulties or
delays in obtaining regulatory approvals to market products and services
resulting from its development efforts; product withdrawals; competitive
factors; difficulties or delays in manufacturing the Company's products;
government and third party reimbursement rates; the commercial success of
VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue
consistent with internal forecasts; and the requirement for substantial
funding to conduct research and development and to expand commercialization
activities. For a further list and description of the risks and
uncertainties the Company faces, see the reports it has filed with the
Securities and Exchange Commission. The Company disclaims any intention or
obligation to update or revise any forward- looking statements, whether as
a result of new information, future events or otherwise.
Editors' Note: This press release is also available under the Media
section of the Company's website at: http://www.millennium.com.
1. American Cancer Society, Overview: Multiple Myeloma, 2005,
http://www.cancer.org
Contacts:
Jennifer Snyder (media) Kyle Kuvalanka (investors)
(617) 448-0281 (857) 498-0818
SOURCE Millennium Pharmaceuticals, Inc.
 back to top
Related links:
http://www.millennium.com/
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
http://www.prnewswire.com/comp/114562.html/
CONTACT:
Media, Jennifer Snyder, +1-617-448-0281, or
Investors, Kyle Kuvalanka, +1-857-498-0818, both for Millennium
Pharmaceuticals, Inc.
|
